ATE121090T1 - Überbrückte cyclische ketale. - Google Patents
Überbrückte cyclische ketale.Info
- Publication number
- ATE121090T1 ATE121090T1 AT92901564T AT92901564T ATE121090T1 AT E121090 T1 ATE121090 T1 AT E121090T1 AT 92901564 T AT92901564 T AT 92901564T AT 92901564 T AT92901564 T AT 92901564T AT E121090 T1 ATE121090 T1 AT E121090T1
- Authority
- AT
- Austria
- Prior art keywords
- ch2ph
- chch
- hydrogen atom
- compounds
- group
- Prior art date
Links
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 9
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 abstract 8
- 101150065749 Churc1 gene Proteins 0.000 abstract 8
- 102100038239 Protein Churchill Human genes 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Fats And Perfumes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919100437A GB9100437D0 (en) | 1991-01-09 | 1991-01-09 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE121090T1 true ATE121090T1 (de) | 1995-04-15 |
Family
ID=10688185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92901564T ATE121090T1 (de) | 1991-01-09 | 1992-01-05 | Überbrückte cyclische ketale. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5278067A (OSRAM) |
| EP (1) | EP0568546B1 (OSRAM) |
| JP (1) | JPH06505472A (OSRAM) |
| AT (1) | ATE121090T1 (OSRAM) |
| AU (1) | AU1157792A (OSRAM) |
| DE (1) | DE69202050D1 (OSRAM) |
| GB (1) | GB9100437D0 (OSRAM) |
| IE (1) | IE920058A1 (OSRAM) |
| IL (1) | IL100611A (OSRAM) |
| MX (1) | MX9200067A (OSRAM) |
| TW (1) | TW208703B (OSRAM) |
| WO (1) | WO1992012156A1 (OSRAM) |
| ZA (1) | ZA92116B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256689A (en) * | 1991-05-10 | 1993-10-26 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5506262A (en) * | 1991-05-10 | 1996-04-09 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5468771A (en) * | 1991-08-07 | 1995-11-21 | Merck & Co., Inc. | Cholesterol lowering compound |
| GB2261374A (en) * | 1991-11-15 | 1993-05-19 | Merck & Co Inc | Inhibitors of farnesyl protein transferase as anti-cancer agents |
| US5262435A (en) * | 1992-02-10 | 1993-11-16 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5302604A (en) * | 1992-03-09 | 1994-04-12 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
| US5294627A (en) * | 1992-08-27 | 1994-03-15 | Merck & Co., Inc. | Directed biosynthesis of biologically active compounds |
| GB9205140D0 (en) * | 1992-03-10 | 1992-04-22 | Glaxo Group Ltd | Chemical compounds |
| GB9205136D0 (en) * | 1992-03-10 | 1992-04-22 | Glaxo Group Ltd | Chemical compounds |
| US5258401A (en) * | 1992-07-10 | 1993-11-02 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5369125A (en) * | 1992-07-17 | 1994-11-29 | Merck & Co., Inc. | Cholesterol-lowering agents |
| US5283256A (en) * | 1992-07-22 | 1994-02-01 | Merck & Co., Inc. | Cholesterol-lowering agents |
| US5270332A (en) * | 1992-08-21 | 1993-12-14 | Merck & Co., Inc. | Cholesteral lowering agents |
| US5326783A (en) * | 1992-08-25 | 1994-07-05 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5310949A (en) * | 1992-09-02 | 1994-05-10 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5278320A (en) * | 1992-09-11 | 1994-01-11 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
| US5322855A (en) * | 1992-10-19 | 1994-06-21 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5332728A (en) * | 1992-11-23 | 1994-07-26 | Bristol-Myers Squibb Company | Method for treating a fungal infection |
| US5447717A (en) * | 1993-02-25 | 1995-09-05 | Merck & Co., Inc. | Cholesterol-lowering agents |
| US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
| US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| US20060263428A1 (en) * | 1993-09-20 | 2006-11-23 | Eugenio Cefali | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
| US6676967B1 (en) * | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| US5712261A (en) * | 1993-10-04 | 1998-01-27 | Magnin; David R. | Method for preventing or treating hypertriglyceridemia |
| US5430055A (en) * | 1994-04-08 | 1995-07-04 | Pfizer Inc. | Inhibitor of squalene synthase |
| US6066336A (en) * | 1997-09-29 | 2000-05-23 | Bristol-Myers Squibb Company | Cholesterol-lowering tablets |
| FR2800375B1 (fr) * | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| CN102154116B (zh) * | 2010-12-22 | 2013-06-12 | 浙江大化生物科技股份有限公司 | 拟茎点霉属内生真菌及其用途 |
| CN102154125B (zh) * | 2011-03-31 | 2013-06-12 | 浙江大化生物科技股份有限公司 | 茎点霉菌株及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH606071A5 (en) * | 1972-05-30 | 1978-10-13 | Ciba Geigy Ag | Fibrinolytic anhydro-furanose ether derivs. |
| US4837205A (en) * | 1986-09-02 | 1989-06-06 | Merck & Co., Inc. | Prodrugs of antihypercholesterolemic compounds |
| IL97251A0 (en) * | 1990-03-21 | 1992-05-25 | Merck & Co Inc | Antihypercholesterolemic 2,8-dioxabicyclo(3,2,1)octane derivatives,their preparation and pharmaceutical compositions containing them |
| US5053425A (en) * | 1990-03-21 | 1991-10-01 | Merck & Co., Inc. | Novel anti-fungal compounds |
| IL97535A0 (en) * | 1990-03-21 | 1992-06-21 | Merck & Co Inc | Squalene synthetase inhibitor dioxabicyclo(1,2,3)octanes,their production and pharmaceutical compositions containing them |
| US5026554A (en) * | 1990-09-13 | 1991-06-25 | Merck & Co., Inc. | Method of inhibiting fungal growth using squalene synthetase inhibitors |
-
1991
- 1991-01-09 GB GB919100437A patent/GB9100437D0/en active Pending
-
1992
- 1992-01-05 AT AT92901564T patent/ATE121090T1/de active
- 1992-01-05 DE DE69202050T patent/DE69202050D1/de not_active Expired - Lifetime
- 1992-01-05 JP JP4502080A patent/JPH06505472A/ja active Pending
- 1992-01-05 WO PCT/EP1992/000014 patent/WO1992012156A1/en not_active Ceased
- 1992-01-05 AU AU11577/92A patent/AU1157792A/en not_active Abandoned
- 1992-01-05 EP EP92901564A patent/EP0568546B1/en not_active Expired - Lifetime
- 1992-01-08 IL IL10061192A patent/IL100611A/en active IP Right Grant
- 1992-01-08 MX MX9200067A patent/MX9200067A/es unknown
- 1992-01-08 IE IE005892A patent/IE920058A1/en unknown
- 1992-01-08 US US07/818,126 patent/US5278067A/en not_active Expired - Fee Related
- 1992-01-08 ZA ZA92116A patent/ZA92116B/xx unknown
- 1992-02-12 TW TW081100973A patent/TW208703B/zh active
-
1993
- 1993-10-26 US US08/141,061 patent/US5409950A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW208703B (OSRAM) | 1993-07-01 |
| US5409950A (en) | 1995-04-25 |
| DE69202050D1 (de) | 1995-05-18 |
| AU1157792A (en) | 1992-08-17 |
| ZA92116B (en) | 1992-10-28 |
| EP0568546A1 (en) | 1993-11-10 |
| MX9200067A (es) | 1992-08-01 |
| JPH06505472A (ja) | 1994-06-23 |
| GB9100437D0 (en) | 1991-02-20 |
| EP0568546B1 (en) | 1995-04-12 |
| US5278067A (en) | 1994-01-11 |
| IE920058A1 (en) | 1992-07-15 |
| IL100611A0 (en) | 1992-09-06 |
| IL100611A (en) | 1995-10-31 |
| WO1992012156A1 (en) | 1992-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE121090T1 (de) | Überbrückte cyclische ketale. | |
| DE69332577D1 (de) | Verfahren zur Herstellung von 13-Ether-Derivaten von Milbemycinen und Zwischenprodukte | |
| CA2146372A1 (fr) | Nouveau procede d'esterification de la baccatine iii et de la desacetyl-10 baccatine iii | |
| DK328579A (da) | Alkylderivater af c-076 forbindelser og fremgangsmaade til fremstilling deraf | |
| FI924227A0 (fi) | Nya alkoxisubstituerade taxaner och farmaceutiska kompositioner innehaollande dessa. | |
| ES8205776A1 (es) | Un procedimiento para la preparacion de una piridilanilina | |
| LU91587I2 (fr) | Agomélatine et ses dérivés pharmaceutiquement acceptables (VALDOXAN) | |
| AU529663B2 (en) | Piperidine alkyl ethers of coumarin and quinoline | |
| DE69013959D1 (de) | Aminobenzolsulfonsäurederivate. | |
| KR910002774A (ko) | 2-아미노펜탄 산 화합물 및 면역 억제제로 그들을 사용하는 방법 | |
| AU6990987A (en) | Macrolide compounds | |
| ES2032335T3 (es) | Nuevos derivados flavonoides 2-piperazinil-2-oxo-etilen sustituidos, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen. | |
| KR900016178A (ko) | 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물 | |
| RU94045867A (ru) | Производные пергидроизоиндола и способы их получения | |
| DE68911855D1 (de) | 4-Substituierte-Anthracyclinone und Anthracyclin-Glycoside und Verfahren zu ihrer Herstellung. | |
| ATE71105T1 (de) | 4-substituierte anthracyclinone und anthracyclinonglycoside und ihre herstellung. | |
| KR960700258A (ko) | 5-0-데소사미닐에리쓰로노라이드 유도체 | |
| GB2276619A (en) | Cyclic ketal derivatives | |
| DK185689D0 (da) | Avermectin-derivater, deres anvendelse til fremstilling af ectoparasiticide, insecticide, acaricide eller anthelmintiske laegemidler, praeparater indeholdende forbindelserne og fremgangsmaade til bekaempelse af skadedyr i afgroeder | |
| ATE244060T1 (de) | Hydroxyester enthaltende kationische zusammensetzungen | |
| CA2126461A1 (fr) | Nouveaux anhydrides d'acides, leur preparation et leur emploi | |
| ATE267593T1 (de) | Ester enthaltende zusammensetzungen zur behandlung von parasitischem befall in organismen | |
| KR920000706A (ko) | N-옥시이미드산 유도체 | |
| DK380382A (da) | 1-aryloxy-3-alkinylamino-2-propanoler og fremgangsmaade til deres fremstilling |